Ovarian Cancer Trial Results
Ovarian Cancer Screening Method Fails to Reduce Deaths from the Disease
(Posted: 07/27/2011) - New results from the NCI-sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.
Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients
(Posted: 06/29/2011) - Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival.
When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009, Updated: 11/05/2010) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.
For Women with BRCA Mutations, Prophylactic Surgery Reduces Cancer Risk
(Posted: 09/23/2010) - Prophylactic surgery to remove the breasts and ovaries is an effective way to reduce the risk of breast and ovarian cancer among women with inherited mutations in the BRCA1 or BRCA2 genes, according to one of the largest prospective studies on the subject to date.
(Posted: 07/27/2011) - New results from the NCI-sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.
Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients
(Posted: 06/29/2011) - Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival.
When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009, Updated: 11/05/2010) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.
For Women with BRCA Mutations, Prophylactic Surgery Reduces Cancer Risk
(Posted: 09/23/2010) - Prophylactic surgery to remove the breasts and ovaries is an effective way to reduce the risk of breast and ovarian cancer among women with inherited mutations in the BRCA1 or BRCA2 genes, according to one of the largest prospective studies on the subject to date.
